Laverock Therapeutics is a pre-clinical drug discovery company which has developed a gene silencing platform for the creation of next generation cell therapies focusing on diabetes and solid tumour immunotherapy.
Laverock is a spin-out from Tropic Biosciences, a biotechnology business that has successfully developed and commercialised its proprietary Gene Editing induced Gene Silencing (GEiGS®) platform in plants, with a focus on improved varieties of tropical crops that are easier to cultivate and healthier for people and the planet. Laverock has an exclusive license to utilise its innovative GEiGS platform in all human therapeutics and has demonstrated that these cellular engineering capabilities are stable, tunable and programmable in mammalian cells, offering improved efficacy and safety and addressing many of the limitations of existing approaches of cell therapies.
Laverock is a spin-out from Tropic Biosciences, a biotechnology business that has successfully developed and commercialised its proprietary Gene Editing induced Gene Silencing (GEiGS®) platform in plants, with a focus on improved varieties of tropical crops that are easier to cultivate and healthier for people and the planet. Laverock has an exclusive license to utilise its innovative GEiGS platform in all human therapeutics and has demonstrated that these cellular engineering capabilities are stable, tunable and programmable in mammalian cells, offering improved efficacy and safety and addressing many of the limitations of existing approaches of cell therapies.
GEiGS is already showing significant potential to transform the safety and efficacy of advanced therapies and we are excited that this new investment will allow us to progress towards pre-clinical candidate selection. We’re pleased to welcome such an experienced group of investors on board, bringing extensive sector expertise which will help us to grow as a company and accelerate the development of targeted, responsive treatments.
David Venables, CEO of Laverock
Meet the lead executive(s)
Subscribe for email updates
Maven VCTs leads £3 million investment in Applied AGI
Maven backs Magnitude Biosciences with follow on funding
Maven strengthens North East portfolio team with two new appointments
Maven appointed as equity manager for the South East Investment Fund
Maven exits WaterBear Education following transformational growth
